Advisory Opinion 22-05: OIG Declines to Impose Sanctions Against Device Manufacturer’s Medicare Cost-Sharing Subsidy in Clinical Trial
On March 16, 2022, the HHS Office of Inspector General published Advisory Opinion 22-05 in which it declined to impose sanctions against a medical device manufacturer that proposes to pay certain cost-sharing obligations of clinical trial participants, including Medicare beneficiaries.
🔒 Members Only · Compliance & Enforcement BriefYou’ve reached the member portion of this brief.Members read the full analysis and the source documents in every case digest, six days a week.
$750/year